uniQure, which develops gene therapies for the treatment of orphan diseases, filed on Thursday with the SEC to raise up to $75 million in an initial public offering. The Amsterdam, Netherlands-based company, which was founded in 1998 and booked $3 million in licensing and collaboration revenue for the 12 months ended September 30, 2013, plans to list on the NASDAQ under the symbol QURE. Jefferies, Leerink Swann and Piper Jaffray are the joint bookrunners on the deal. No pricing terms were disclosed.
